Nanoform Finland
2.54 EUR +3.04%3,389 investors are following this company
Nanoform Finland is a medical technology company. The company specializes in the research and development of technical products used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. The customers consist of companies in the global pharmaceutical industry. Nanoform Finland mainly operates in the Nordic market and is headquartered in Helsinki.
Revenue
2.57M
EBIT %
-874.71 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Finland
NANOFH
Daily low / high price
2.395 / 2.57
EUR
Market cap
199.25M EUR
Turnover
106.64K EUR
Volume
43K
Latest videos
Financial calendar
Interim report
2024-05-30
Interim report
2024-08-29
Interim report
2024-11-22
Annual report
2025-02-27
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Handelsbanken | 7.7 % | 7.7 % |
Edward Hæggström | 6.9 % | 6.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Resolutions of Nanoform Finland Plc's Annual General Meeting on April 16, 2024
Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools